Introduction {#Sec1}
============

Life on Earth has a long and storied history with the gas hydrogen sulfide (H~2~S). Before the advent of molecular oxygen-rich environments 2.3 billion years ago^[@CR1]^, life depended on the utilization and consumption of H~2~S for many of its biochemical and cellular processes^[@CR2]^. Paradoxically, several mass extinction events coincide with, and are hypothesized to be causative of, toxic H~2~S levels in the atmosphere and oceans^[@CR3]^. Thus, life has evolved with H~2~S serving as both an essential nutrient and selective pressure, resulting in cellular pathways for its controlled production, utilization, and/or detoxification.

In mammals, enzymatically produced H~2~S and its associated hydrosulfide anion (HS^−^) and sulfide anion (S^2−^), herein collectively referred to as H~2~S^[@CR4]^, are primarily derived from the metabolism of sulfur-containing amino acids (SAAs), specifically cysteine and homocysteine^[@CR5]^. Three enzymes historically responsible for this production include cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL), which are part of the transsulfuration pathway (Fig. [1a](#Fig1){ref-type="fig"}), and 3-mercaptopyruvate sulfurtransferase (3-MST)^[@CR6],[@CR7]^ (Fig. [1b](#Fig1){ref-type="fig"}). The enzymatic activities of CBS and CGL, while promiscuous in terms of substrates and yields^[@CR6]^, require the pyridoxal phosphate (PLP) cofactor form of Vitamin B~6~ (VitB~6~) in α,β-elimination or β-replacement of the SAA thiol group to produce H~2~S^[@CR8],[@CR9]^. However, although PLP is not required for 3-MST activity, it is required for its upstream enzyme cysteine aminotransferase (CAT) to degrade cysteine to 3-mercaptopyruvate, which serves as substrate for 3-MST to produce sulfane sulfur and eventual H~2~S^[@CR10]^. Thus, enzymatic production of H~2~S from SAAs in mammalian tissues is dependent on PLP.Fig. 1Enzymatic and non-enzymatic H~2~S production is tissue specific. **a**, **b** Generalized models of Vitamin B~6~ (VitB~6~) (PLP)-dependent enzymatic H~2~S production. H~2~S is generated from cysteine or homocysteine via the transsulfuration pathway enzymes, cystathionine β-synthase (CBS), and cystathionine γ-lyase (CGL) (**a**), or through the stepwise deamination of cysteine to 3-mercaptopyruvate (3-MP) by cysteine/asparatate aminotransferase (CAT) and release of H~2~S via 3-mercaptopyruvate sulfurtransferase (3-MST) (**b**). **c**, **d** H~2~S production from tissue extracts (**c**) (*n* = 3/group) or from plasma and red blood cells (RBCs) (**d**) (*n* = 5/group) collected from *CGL* WT and *CGL* KO mice in the presence of [l]{.smallcaps}-cysteine and PLP. Asterisk indicates the significance of the difference versus *CGL* WT; \**P* \< 0.05. **e**, **f** H~2~S production capacity of tissue extracts, plasma, and RBCs from *CGL* WT mice in the presence of [l]{.smallcaps}-cysteine and PLP ± Proteinase K (Prot. K) pretreatment as measured after 3 h incubation (**e**) or 16 h incubation (**f**), *n* = 3/group. Asterisk indicates the significance of the difference versus sample without Prot. K pretreatment; \**P* \< 0.05. **g** Non-enzymatic H~2~S production in DMEM media or DMEM/F12 media in the presence of cysteine and/or PLP; *n* = 3/group. Asterisk indicates the significance of the difference vs. media-only group; \**P* \< 0.05. All data were presented as mean ± SEM

Deficiencies in endogenous enzymatic H~2~S production and levels are associated with detrimental health effects^[@CR11]^. These include atherosclerosis^[@CR12]^, hypertension^[@CR13]^, and neurodegenerative disorders^[@CR14]^. In addition, CGL deficiencies result in the failure to positively respond and adapt to dietary^[@CR15],[@CR16]^ and ischemic^[@CR17]^ preconditioning. Conversely, increasing endogenous H~2~S production capacity and/or levels provides healthspan and lifespan extending benefits in model organisms^[@CR11]^. Thus, discovering new mechanisms that regulate and/or augment endogenous H~2~S pose novel scientific and therapeutic avenues.

Opposite of enzymatic synthesis pathways, endogenous production of H~2~S through non-enzymatic processes in mammalian tissues is not well understood or characterized. Sulfur-containing molecules found in garlic act as H~2~S donors when reduced with glutathione in red blood cells (RBCs)^[@CR18]^ and thiosulfate serves as a source for H~2~S production under hypoxic conditions in select tissues^[@CR19]^. However, whether SAAs serve as substrates for non-enzymatic H~2~S production in mammalian tissues under normal physiological conditions, the chemical mechanism(s) involved, and biological contexts are yet to be determined. In the current study, we investigate the status of non-enzymatic H~2~S production in various tissues and the chemical mechanism. Specifically, we uncover the biological relevance of VitB~6~, either in the pyridoxal or PLP form, and free- or hemin/heme-bound iron in catalyzing H~2~S from the SAA cysteine in vitro and in blood ex vivo using a variety of H~2~S- and metabolite-detecting approaches.

Results {#Sec2}
=======

Tissue-specific enzymatic and non-enzymatic H~2~S production {#Sec3}
------------------------------------------------------------

To establish enzymatic and non-enzymatic contributions to H~2~S production in various mammalian tissues, the protein expression of CBS, CGL, and 3-MST and H~2~S production capacities were determined. Expression of CBS and CGL were strongest in the liver and kidney, and 3-MST in the brain (Supplementary Fig. [1A,B](#MOESM1){ref-type="media"}). Other tissues, such as spleen, pancreas, abdominal white fat, testis, lung, heart, and skeletal muscle had relatively low expression of these three proteins (Supplementary Fig. [1A,B](#MOESM1){ref-type="media"}). As CGL contributes to the majority of enzymatic H~2~S production under physiological conditions, at least in the liver^[@CR20]^, H~2~S production capacity was tested in *CGL* wild-type (WT) and knockout (KO) mice using the lead acetate/lead sulfide method^[@CR21]^ with [l]{.smallcaps}-cysteine (L-Cys) as substrate and PLP as cofactor. H~2~S production was strongest in the liver and kidney from *CGL* WT mice, and *CGL* KO reduced production in these two tissues (Fig. [1c](#Fig1){ref-type="fig"} and Supplementary Fig. [1C](#MOESM1){ref-type="media"}). H~2~S production in other tissues, plasma, and RBCs, albeit low compared with that in the liver and kidney, were not decreased due to *CGL* deficiency (Fig. [1c, d](#Fig1){ref-type="fig"}).

We next tested whether CGL-independent H~2~S production is due to other H~2~S-producing enzymes or via a non-enzymatic mechanism. Pretreatment of tissues ex vivo with proteinase K (Prot. K) to remove enzymatic activity decreased H~2~S production in the liver and kidney (Fig. [1e](#Fig1){ref-type="fig"} and Supplementary Fig. [1D](#MOESM1){ref-type="media"}), whereas it unexpectedly increased H~2~S production in the spleen, heart, lung, muscle, bone marrow, and plasma, with the greatest increase in RBCs (Fig. [1e, f](#Fig1){ref-type="fig"}). Thus, hepatic and renal H~2~S production is predominantly enzymatic and driven by CGL, whereas non-enzymatic production is a major contributor in other tissues and in circulation.

Additional evidence for non-enzymatic H~2~S production was detected in vitro with cell culture media. Dulbecco's modified Eagle's medium (DMEM) + 10% serum alone produced H~2~S, albeit at a lower level compared with NCTC 1496 liver cells growing in DMEM + 10% serum, when spiked with L-Cys and PLP (Supplementary Fig. [1E](#MOESM1){ref-type="media"}). We next tested media without serum/plasma to serve as a catalyst for H~2~S production. L-Cys supplementation in addition to the cysteine/cystine basally present in media (Supplementary Table [1](#MOESM1){ref-type="media"}) DMEM and DMEM/F12 produced H~2~S, which was further enhanced with additional PLP (Fig. [1g](#Fig1){ref-type="fig"} and Supplementary Fig. [1F](#MOESM1){ref-type="media"}). Thus, PLP enhanced non-enzymatic H~2~S production from L-Cys in multiple tissues and in cell culture media. However, the identity of the catalytic factor(s) besides pyridoxine(phosphate) in the media and tissues that gives rise to non-enzymatic H~2~S production is yet to be identified.

Fe^3+^ and PLP coordinately catalyze H~2~S production from L-Cys {#Sec4}
----------------------------------------------------------------

Metal ions serve enzymatic and non-enzymatic catalytic roles^[@CR22]^. Metal ion formulations for DMEM and DMEM/F12 (Supplementary Table [1](#MOESM1){ref-type="media"}) include iron (Fe^3+^), zinc (Zn^2+^), copper (Cu^2+^), and magnesium (Mg^2+^). These same metals are found in milligram to gram amounts in the human body, with iron and copper previously indicated to catalyze H~2~S and/or sulfide production from SAAs in coordination with pyridoxal under non-physiological conditions of temperature and/or pH^[@CR23],[@CR24]^. We hypothesized that one or more of these metal ions catalyze non-enzymatic H~2~S production under physiological conditions. Ethylenediaminetetraacetic acid (EDTA), a metal ion chelator, inhibited H~2~S production in DMEM/F12 media (Supplementary Fig. [2](#MOESM1){ref-type="media"}). We next identified metal ions that act as catalysts for PLP-dependent H~2~S production from L-Cys in phosphate-buffered saline (PBS) at pH 7.4 and 37 °C (Fig. [2a](#Fig2){ref-type="fig"}). Iron (Fe^3+^) showed the greatest catalytic ability, followed by aluminum (Al^3+^) and, to a lesser extent, manganese (Mn^2+^). The other metal ions, Zn^2+^, Cu^2+^, Pb^2+^, Ca^2+^, and Mg^2+^, did not stimulate H~2~S production (Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2Fe^3+^ and PLP coordinate to catalyze H~2~S production from [l]{.smallcaps}-cysteine under physiological conditions. **a** H~2~S production catalyzed by inorganic metal ions as indicated, in the reaction mixture of [l]{.smallcaps}-cysteine and PLP; *n* = 6/group. Asterisk indicates the significance of the difference versus the [l]{.smallcaps}-cysteine and PLP alone reaction mixture control group; \**P* \< 0.05. **b**--**e** The effect of pH (**b**; *n* = 6/group), temperature (**c**; *n* = 5/group), O~2~ (**d**; *n* = 5/group), and Fe^3+^ concentration (**e**; *n* = 6/group) on H~2~S production from reaction mixtures containing [l]{.smallcaps}-cysteine, PLP, and Fe^3+^ (**b**, **c**, **e**) or the [l]{.smallcaps}-cysteine and PLP mixture group (**d**); \**P* \< 0.05. **f** H~2~S production in PBS ± [l]{.smallcaps}-cysteine ± PLP, ±Fe^3+^, and with the pretreatment of EDTA; *n* = 6/group. Asterisk indicates the significance of the difference vs. the [l]{.smallcaps}-cysteine and PLP mixture group, and pound indicates the significance of the difference between PBS ± [l]{.smallcaps}-cysteine ± PLP, ±Fe^3+^ with and without EDTA; \*,^\#^*P* \< 0.05. All data were presented as mean ± SEM

We next focused on iron, as it is abundant in the body, had the greatest catalytic activity (Fig. [2a](#Fig2){ref-type="fig"}), and is predominantly found in RBCs, which had the greatest increase in non-enzymatic H~2~S production after Prot. K treatment (Fig. [1e](#Fig1){ref-type="fig"}). Fe^3+^-induced production was optimum at a physiological pH 7.0--7.4 (Fig. [2b](#Fig2){ref-type="fig"}), temperature of 37 °C (Fig. [2c](#Fig2){ref-type="fig"}), normoxic 20% oxygen conditions (Fig. [2d](#Fig2){ref-type="fig"}), and was dose dependent in the µM range (Fig. [2e](#Fig2){ref-type="fig"}). Although Fe^3+^ somewhat catalyzed H~2~S from L-Cys without PLP present, possibly due to direct thiol oxidation and/or an alternate chemical mechanism, the addition of PLP greatly increased the production capacity (Fig. [2f](#Fig2){ref-type="fig"}). This indicates PLP serves as a vital cofactor for the formation of H~2~S from enzymatic and non-enzymatic Fe^3+^-mediated catalysis. EDTA chelation of Fe^3+^ dampened H~2~S production in PBS (Fig. [2f](#Fig2){ref-type="fig"}) and DMEM/F12 (Supplementary Fig. [2](#MOESM1){ref-type="media"}). Taken together, H~2~S is produced via the coordinated catalysis of L-Cys by Fe^3+^ and PLP under physiological conditions of pH, temperature, and oxygen.

Gaseous and aqueous detection of Fe^3+^ and PLP-catalyzed H~2~S {#Sec5}
---------------------------------------------------------------

Additional sensitive and selective headspace or in-solution H~2~S detection techniques were used to confirm and expand upon our lead acetate/lead sulfide results presented in Fig. [1](#Fig1){ref-type="fig"} and Fig. [2](#Fig2){ref-type="fig"}. The Jerome J605, a gold film H~2~S analyzer capable of measuring H~2~S in the 3 parts per billion (p.p.b.) to 1 parts per million (p.p.m.) range^[@CR25]^ (Supplementary Fig. [3A](#MOESM1){ref-type="media"}), was configured to detect H~2~S produced from 1 mL reaction mixtures in 6 mL headspace vials (Fig. [3a, b](#Fig3){ref-type="fig"} and Supplementary Fig. [3B](#MOESM1){ref-type="media"}). Incubation of the complete reaction mixture containing supraphysiological levels of L-Cys, PLP, and Fe^3+^ in PBS for 1 h at 37 °C produced detectable H~2~S between 40 and 65 p.p.b. (Fig. [3a](#Fig3){ref-type="fig"}). H~2~S was not detected in the two control reaction solutions containing only PBS with or without L-Cys (Fig. [3a](#Fig3){ref-type="fig"}). Incubation of physiologically relevant amounts of L-Cys, PLP, and Fe^3+^ in PBS for 6 h produced detectable H~2~S between 3.5 and 4.5 p.p.b. (Fig. [3b](#Fig3){ref-type="fig"}). However, reaction mixtures not containing this full complement of substrate and catalysts produced no detectable H~2~S. We further confirmed H~2~S production from these physiologically relevant concentrations using the lead acetate/lead sulfide method with a relatively long 24 h incubation/exposure time at 37 °C (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3Detection of headspace and dissolved H~2~S catalyzed by Fe^3+^ and PLP with [l]{.smallcaps}-cysteine as substrate. **a**, **b** H~2~S levels (parts per billion; p.p.b.) in 6 mL headspace vials detected using the Jerome J605 after (**a**) 1 h incubation of reaction mixture containing supraphysiological concentration of [l]{.smallcaps}-cysteine (10 mM), PLP (1 mM), and Fe^3+^ (50 µM); *n* = 3/group, or after (**b**) 6 h incubation of reaction mixture containing more relevant physiological concentrations of [l]{.smallcaps}-cysteine (500 µM), PLP (500 nM), and Fe^3+^ (50 µM); *n* = 3/group. Asterisk indicates the significance of the difference versus the PBS background control; \**P* \< 0.05. **c** Lead acetate/lead sulfide H~2~S production analysis under similar physiological conditions as in **b** with overnight exposure at 37 °C; *n* = 6/group. **d**, **e** Headspace H~2~S detected in the selected ion flow tube mass spectrometry (SIFT-MS) with **d** quantitative targeted scan for H~2~S; *n* = 1 for air control and NaHS groups, and *n* = 2 for PBS/PLP/L-Cys and PBS/PLP/L-Cys/Fe(III) groups, and **e** truncated mass spectrum over the range of mass-to-charge (*m*/*z*) shown in H~3~O^+^ reagent ion, measuring the product ions generated in the reaction with H~3~O^+^, being the *m*/*z* 35 product ion. The precursor ion signals (H~3~O^+^·(H~2~O)~0,1,2~ as appropriate) and the product ion signals are indicated. The concentrations of the trace gases are given in parts per million (p.p.m.). For full mass spectrum over the *m*/*z*, please see Supplementary Fig. [3c, d](#MOESM1){ref-type="media"}. **f** Time-dependent detection of dissolved H~2~S using the fluorogenic AzMC probe (Exc 350 nm/Emi 445 nm) from various reaction mixtures; *n* = 6/group. All data were presented as mean ± SEM

We next employed selected ion flow tube mass spectrometry (SIFT-MS)^[@CR26],[@CR27]^ as a quantitative, selective, and sensitive third headspace analysis method. Incubation of the complete reaction mixture containing L-Cys, PLP, and Fe^3+^ in PBS in a sealed 20 mL headspace vial for 30 min produced 1.024 p.p.m. H~2~S (Fig. [3d](#Fig3){ref-type="fig"}). H~2~S from control reaction mixtures lacking Fe^3+^ and in the control room air was detected at 0.008 and 0.001 p.p.m., respectively. Comprehensive volatile molecule analysis and full spectrum over the range of mass-to-charge (*m*/*z*) in H~3~O^+^ reagent ion mode^[@CR27],[@CR28]^ was used for samples with reaction mixtures of PLP, L-Cys, ±Fe^3+^ to detect all potential sulfide products in the headspace. H~2~S, being the *m*/*z* 35 product ion H~3~S^+[@CR27],[@CR28]^, was the sole product detected in the full reaction mixture not present in the control lacking Fe^3+^ (Fig. [3e](#Fig3){ref-type="fig"} and Supplementary Fig. [3C,D](#MOESM1){ref-type="media"}). No additional smaller or larger mass sulfide species were detected (Supplementary Fig. [3C,D](#MOESM1){ref-type="media"}), confirming H~2~S as the major sulfide product.

H~2~S exists not just in the gas phase but is soluble in aqueous and organic solutions as well. We next determined the presence of non-enzymatically produced H~2~S in solution using the sulfide-sensitive 7-azido-4-methylcoumarin (AzMC) fluorogenic probe, which increases in florescence intensity at *λ*~Ex/Em~ = 350/445 nm upon H~2~S-mediated reduction^[@CR29],[@CR30]^. Time-dependent increased florescence intensity was detected only with the full reaction mixture containing PBS, L-Cys, PLP, and Fe^3+^ (Fig. [3f](#Fig3){ref-type="fig"}). Thus, H~2~S produced from iron- and PLP-coordinated catalysis of L-Cys is detectable as a gas and in solution.

Cysteine as optimum substrate for Fe^3+^- and PLP-catalyzed H~2~S {#Sec6}
-----------------------------------------------------------------

Enzymatic H~2~S production utilizes SAAs as substrate, mainly L-Cys and homocysteine^[@CR6]^. Although we have shown L-Cys is a substrate for Fe^3+^/PLP-driven non-enzymatic H~2~S production, it is not known whether other SAAs serve as substrates. We tested SAAs L-Cys, D-Cys, [dl-]{.smallcaps}Homocysteine, [l]{.smallcaps}-Methionine, and the tripeptide Glutathione (Fig. [4a](#Fig4){ref-type="fig"}) for production of H~2~S via PLP and Fe^3+^ catalysis. H~2~S production was specific for L- and D-Cys, and was detected after 2.5 h incubation (Fig. [4b](#Fig4){ref-type="fig"}). This is in contrast to enzymatic production via the liver, in which L-Cys, but not D-Cys, serves as a substrate (Supplementary Fig. [4A](#MOESM1){ref-type="media"}). Thus, the isomeric form, although important for enzymatic production, does not impact non-enzymatic production. Homocysteine did not provide the same kinetics as cysteine, as detectable H~2~S production by [dl]{.smallcaps}-Homocysteine was only apparent after a 16 h incubation (Fig. [4b](#Fig4){ref-type="fig"} and Supplementary Fig. [4B](#MOESM1){ref-type="media"}). This was not due to the DL-isomeric form, as DL- and L-Homocysteine performed similarly at 2 and 24 h incubations (Supplementary Fig. [4C](#MOESM1){ref-type="media"}). Acetylation of the amino group of cysteine, termed *N*-acetylcysteine (NAC) (Fig. [4c](#Fig4){ref-type="fig"}), blocked non-enzymatic H~2~S production (Fig. [4d](#Fig4){ref-type="fig"}). Cystine (Supplementary Fig. [4D](#MOESM1){ref-type="media"}), the oxidized dimer form of cysteine, failed to serve as substrate for H~2~S production (Supplementary Fig. [4E](#MOESM1){ref-type="media"}). Thus, cysteine in the L- or D-form serves as the best SAA substrate for H~2~S production via Fe^3+^- and PLP-coordinated catalysis, and this requires access to its amino group.Fig. 4[l]{.smallcaps}- and [d]{.smallcaps}-Cysteine, but not other SAAs, act as substrate for rapid H~2~S production catalyzed by Fe^3+^ and PLP. **a** Chemical structure of the sulfur amino acids (SAAs). **b** H~2~S production capacity as determined by the lead acetate/lead sulfide method after 2.5 h incubation with different SAAs as substrate catalyzed by Fe^3+^ and PLP; *n* = 6/group. Asterisk indicates the significance of the difference versus the [l]{.smallcaps}-cysteine and PLP-alone control mixture group; \**P* \< 0.05. **c** Chemical structure of *N*-acetylcysteine (NAC). **d** H~2~S production capacity with NAC as substrate in the presence of Fe^3+^ and PLP; *n* = 4/group. **e** Chemical structures of PLP and pyridoxal. **f**, **g** Selectivity of PLP and pyridoxal as co-factors for enzymatic H~2~S production in liver extract (**f**); *n* = 6/group, and non-enzymatic iron-catalyzed H~2~S production (**g**); *n* = 6/group. Asterisk indicates the significance of the difference versus the control PLP/Pyridoxal-null reaction mixture 0; \**P* \< 0.05. Data were presented as mean ± SEM

Besides the above SAAs, garlic-derived polysulfides are reduced by glutathione to produce H~2~S in human RBCs^[@CR18]^. We tested whether they serve as substrates for Fe^3+^- and PLP-catalyzed H~2~S production. Two major volatile sulfur-containing garlic components, diallyl disulfide (DADS) and diallyl trisulfide (DATS) (Supplementary Fig. [4F](#MOESM1){ref-type="media"}), in addition to raw garlic blend, did not serve as compounds for H~2~S detection via the lead acetate/lead sulfide method when incubated solely in PBS or substrates for H~2~S production when incubated with Fe^3+^ and PLP (Supplementary Fig. [4G](#MOESM1){ref-type="media"}). In addition, the volatile sulfur-containing reducing reagents, dithiothreitol (DTT) and 2-mercaptoethanol (2ME) (Supplementary Fig. [4H](#MOESM1){ref-type="media"}), did not serve as compounds for H~2~S detection when incubated solely in PBS or substrates for H~2~S production when incubated with Fe^3+^ and PLP (Supplementary Fig. [4I, J](#MOESM1){ref-type="media"}). However, DTT reacted with Fe^3+^ independent of PLP and released H~2~S (Supplementary Fig. [4J](#MOESM1){ref-type="media"}), thus delivering H~2~S in a mechanism distinct from the reaction with cysteine. Importantly, the failure of these volatile organic sulfur compounds to form brown spots (lead sulfide) on the lead acetate paper independently of any chemical reaction supports the selectivity of the lead acetate/lead sulfide detection method for H~2~S and less so for other volatile sulfur-containing compounds.

The bioactive phosphorylated form of VitB~6~, PLP (Fig. [4e](#Fig4){ref-type="fig"}), is required as a cofactor for a variety of enzymatic reactions, including H~2~S biogenesis^[@CR10]^. However, it is not known whether the phosphorylated form is required for non-enzymatic production of H~2~S with L-Cys as substrate. The majority of VitB~6~ in the body does not exists in the PLP form, but in the pyridoxal form^[@CR31]^ (Fig. [4e](#Fig4){ref-type="fig"}). Thus, if non-enzymatic H~2~S production occurs with PLP and pyridoxal, it signifies this reaction is potentially more prevalent in vivo. We tested PLP and pyridoxal for both enzymatic (Fig. [4f](#Fig4){ref-type="fig"}) and non-enzymatic (Fig. [4g](#Fig4){ref-type="fig"}) H~2~S production. Liver-derived enzymatic H~2~S production required only PLP (Fig. [4f](#Fig4){ref-type="fig"}). Conversely, Fe^3+^-catalyzed non-enzymatic production of H~2~S occurred similarly with PLP and pyridoxal, signifying the phosphate group as dispensable (Fig. [4g](#Fig4){ref-type="fig"}). This, in combination with the requirement for access to the amino group of cysteine, gives clues to the chemical reaction mechanism of iron- and VitB~6~-coordinated production of H~2~S.

Multi-step mechanism for Fe^3+^- and VitB~6~-catalyzed H~2~S {#Sec7}
------------------------------------------------------------

Based on the intermolecular interactions between PLP with cysteine^[@CR10]^ and serine^[@CR32]^ in the context of enzyme-catalyzed elimination reactions, we hypothesized the enzyme-free chemical reaction to produce H~2~S consists of five generalized steps (Fig. [5a](#Fig5){ref-type="fig"}): (i) nucleophilic attack by the free amino group of cysteine on the aldehyde group of PLP or pyridoxal forms a Schiff base and subsequent cysteine-aldimine; (ii) deprotonation at the α-position of cysteine to form a quinonoid intermediate stabilized via the electron sink properties of PLP; (iii) Fe^3+^-catalyzed elimination of the thiol group forms a desulfurated aldimine and releases H~2~S; (iv) removal and hydrolyzation of the desulfurated cysteine to produce pyruvate, ammonia (NH~3~), and regenerate PLP (or pyridoxal), and (v) in the absence of Fe^3+^, a five-member thiazolidine ring is made from the cysteine-aldimine product from step (i). In the following section, we present empirical data along with published studies supporting the proposed chemical mechanism.Fig. 5Mechanistic model for Fe^3+^- and PLP-catalyzed H~2~S production. **a** Proposed reaction model for H~2~S production from cysteine, PLP, and Fe^3+^: (i) the nucleophilic attack by the free amino group of cysteine on PLP forms a Schiff base, the cysteine-aldimine; (ii) deprotonation at α-position of cysteine leads to the formation of a quinonoid intermediate; (iii) the elimination of ‒SH group catalyzed by Fe^3+^; and (iv) the desulfurated aldimine is hydrolyzed to produce pyruvate, NH~3~, and regenerate PLP; (v) in the absence of Fe^3+^, a thiazolidine ring is formed from cysteine-aldimine product from step (i), offering UV/VIS peak absorbance at 333 nm^[@CR37]^. **b** AOAA, but not PAG, inhibits Fe^3+^- and PLP-catalyzed H~2~S production; *n* = 3/group. Asterisk indicates the significance of the difference vs. the [l]{.smallcaps}-cysteine, Fe^3+^, and PLP control reaction mixture group; \**P* \< 0.05. **c** Detection of PLP Schiff base by UV/VIS spectrophotometer. Absorbance of PLP in the absence or presence of tested sulfur amino acids was measured in the spectrum of 310--435 nm. The formation of Schiff base at \~330 nm is indicated by the shift of the peak with the addition of tested sulfur amino acids from \~390 nm. **d** Changes in absorbance in reaction mixture of PLP ± cysteine ± Fe^3+^ with reaction time. Loss of absorbance at 330 nm and gain at 390 nm after 24 h incubation in reaction mixture of cysteine with Fe^3+^ and PLP indicate Fe^3+^ consumes the substrate of cysteine and PLP is regenerated. **e** Pyruvate formation in reaction mixture of cysteine and PLP, ±FeCl~3~; *n* = 4/group. Data are measured colorimetrically at absorbance of 570 nm showing quantity (nmol) per ml H~2~S reaction mixture. All data were presented as mean ± SEM

In (i), the amino group of cysteine attacks the aldehyde group of PLP to form the Schiff base and subsequent cysteine-aldimine. Blocking this interaction via acylation of the amino group on cysteine inhibited the production of H~2~S (Fig. [4d](#Fig4){ref-type="fig"}). Similarly, aminooxyacetic acid (AOAA) (Supplementary Fig. [5A](#MOESM1){ref-type="media"}), a proposed inhibitor of PLP-dependent enzymes and of enzymatic H~2~S production^[@CR33]^ (Supplementary Fig. [5B](#MOESM1){ref-type="media"}) due to it outcompeting the enzyme to form a Schiff base linkage with the aldehyde group of PLP^[@CR30],[@CR34]^, inhibited non-enzymatic H~2~S production (Fig. [5b](#Fig5){ref-type="fig"}). However, propargylglycine (PAG) (Supplementary Fig. [5A](#MOESM1){ref-type="media"}), an inhibitor of CGL (Supplementary Fig. [5B](#MOESM1){ref-type="media"}) due to it covalently modifying the enzyme vs. PLP itself^[@CR30],[@CR33]^, had no effect on non-enzymatic H~2~S production (Fig. [5b](#Fig5){ref-type="fig"}).

We further confirmed the requirements for the formation of the cysteine-aldimine via UV/Spec absorbance analysis of the PLP-derived Schiff base with SAAs and AOAA by examining the shift in *λ*~Max~, which is \~388 nm for free PLP at physiological pH, to a peak in the 320--330 nm range for the Schiff base^[@CR35]^ (Fig. [5c](#Fig5){ref-type="fig"}, Supplementary Fig. [5C,D,E](#MOESM1){ref-type="media"}, and Table [1](#Tab1){ref-type="table"}). As a control, the SAAs alone did not display a distinctive *λ*~Max~ in this region (Supplementary Fig. [5C](#MOESM1){ref-type="media"}). PLP with AOAA resulted in a complete loss of the 388 nm peak and a shift to 324 nm (Supplementary Fig. [5D](#MOESM1){ref-type="media"}). PLP with L-Cys or [dl]{.smallcaps}-homocysteine, the two SAAs that produced H~2~S albeit with different kinetics, displayed a loss of *λ*~Max~ 388 nm and a shift to the 320--330 nm peak (Fig. [5c](#Fig5){ref-type="fig"} and Supplementary Fig. [5D](#MOESM1){ref-type="media"}). SAAs that failed to serve as substrate for H~2~S production (Fig. [4b, d](#Fig4){ref-type="fig"} and Supplementary Fig. [4E](#MOESM1){ref-type="media"}) did not remove the *λ*~Max~ at 388 nm and formed no peaks or incomplete peaks in the 320--330 nm range (Fig. [5c](#Fig5){ref-type="fig"}, Supplementary Fig. [5E](#MOESM1){ref-type="media"}, and Table [1](#Tab1){ref-type="table"}). Notably, in the absence of Fe^3+^, a thiazolidine ring can be formed from the cysteine-aldimine product in step (i) by intramolecular attack of the sulfhydryl group to the imine carbon atom^[@CR36]^, which also has a *λ*~Max~ in the 320--330 nm range^[@CR37]^. Therefore, the *λ*~Max~ in the 320--330 nm range detected in the current study indicates cysteine-aldimine and/or thiazolidine, and the presence of iron prevents and/or reopens the thiazolidine ring for downstream sulfide removal. The role for Fe^3+^ catalytically consuming cysteine and subsequent regeneration of the PLP cofactor was also investigated via UV/Spec analysis (Fig. [5d](#Fig5){ref-type="fig"}). Addition of L-Cys to PLP immediately shifted the *λ*~Max~ from \~388 nm to 320--330 nm, indicative of the Schiff base/thiazolidine ring (Fig. [5d](#Fig5){ref-type="fig"}). Further addition of Fe^3+^ to this reaction mixture resulted in loss of *λ*~Max~ at 320--330 nm and gain at \~388 nm after a 24 h incubation at 37 °C (Fig. [5d](#Fig5){ref-type="fig"}).Table 1UV/Vis spectrophotometer-based detection of Schiff base formation between PLP and sulfur-containing amino acidsReactants1st Peak absorbance wavelength (nm)*λ*~Max~ OD\
at peak 12nd Peak absorbance\
wavelength (nm)λ~Max~ OD\
at peak 2PLP386--3880.62NDND*PLP* *+* *L-Cys*3300.63NDND*PLP* *+* *DL-Hmcys*328--3300.74NDNDPLP + L-Met4040.54NDNDPLP + GSH328--3300.42384--3960.4PLP + NAC3280.38386--3880.49PLP + Cystine3900.52NDNDThe sulfur-containing amino acids selected as substrate for non-enzymatic H~2~S production are in italic. The numerical values presented in this table correspond to the plotted values in Fig. [5c](#Fig5){ref-type="fig"} and Supplementary Fig. [5c--e](#MOESM1){ref-type="media"}. *DL-Hmcys* [dl]{.smallcaps}-homocysteine, *GSH* glutathione, *L-Cys* [l]{.smallcaps}-cysteine, *L-Met* [l]{.smallcaps}-methionine, *NAC* *N*-acetylcysteine, *ND* not detected, *PLP* pyridoxal phosphate

We next utilized a liquid chromatography-tandem MS (LC-MS/MS) metabolomics platform to identify intermediaries and final products of the proposed reaction. Combinations of L-Cys, PLP, and Fe^3+^ were incubated in PBS at 37 °C before analysis. L-Cys with PLP resulted in the identification of the cysteine-aldimine/cysteine-quinonoid (Table [2](#Tab2){ref-type="table"} and Supplementary Fig. [5H](#MOESM1){ref-type="media"}). All of the detectable intermediates and products, including aldimine and pyruvate, were only found with the addition of Fe^3+^ (Table [2](#Tab2){ref-type="table"} and Supplementary Fig. [5I,J,M](#MOESM1){ref-type="media"}). In addition, Fe^3+^ lowered the peak heights for cysteine and cysteine-aldimine/cysteine-quinonoid, indicating Fe^3+^ is required to catalyze the reaction beyond the cysteine-aldimine/thiazolidine step (Table [2](#Tab2){ref-type="table"} and Supplementary Fig. [5I,J](#MOESM1){ref-type="media"}). As Fe^3+^-catalyzed H~2~S production is enhanced at 37 °C (Fig. [2c](#Fig2){ref-type="fig"}), we examined the peak heights of the full reaction incubated at 37 °C vs. 4 °C to determine which steps are temperature dependent. Peak heights were lower for cysteine and cysteine-aldimine/cysteine-quinonoid and higher for pyruvate at 37 °C compared with 4 °C (Table [2](#Tab2){ref-type="table"} and Supplementary Fig. [5I-M](#MOESM1){ref-type="media"}). However, the formation of the cysteine-aldimine/cysteine-quinonoid still occurred at 4 °C (Table [2](#Tab2){ref-type="table"} and Supplementary Fig. [5L](#MOESM1){ref-type="media"}). Time-dependent pyruvate formation was additionally confirmed using a colorimetric-based assay (Fig. [5e](#Fig5){ref-type="fig"}). Fe^3+^ enhanced the rate of pyruvate formation compared with the reaction mixture lacking Fe^3+^ (Fig. [5e](#Fig5){ref-type="fig"}). Taken together, the initial step of Schiff base/thiazoladine and cysteine-aldimine/cysteine-quinonoid formation between cysteine and VitB~6~ is not temperature dependent and does not require Fe^3+^, but does require free access to both the aldehyde group on VitB~6~ and the amino group of cysteine. However, subsequent steps in the reaction require Fe^3+^ and physiological temperatures to efficiently proceed and ultimately produce H~2~S, pyruvate, NH~3~, and recycle VitB~6~.Table 2Expected intermediates and products identified and their relative yields as determined from LC-MS/MS full scan extracted ion chromatogramsReactants[l]{.smallcaps}-CysteineCysteine-aldimine/cysteine-quinonoidAldiminePyruvateLC-MS/MS products identified L-Cys+NDNDND L-Cys + PLP++NDND *L-Cys* *+* *PLP* *+* *Fe*^3+^++++LC-MS/MS chromatographic peak heights L-Cys274,723NDNDND L-Cys + PLP270,622127,0041NDND* L-Cys* + *PLP* + *Fe*^3+^ (*37* °C)686843,17734,50025,200 L-Cys + PLP + Fe^3+^ (4 °C)10,387338,58132,50010,450Italic text indicates reactions and conditions favorable for H~2~S production. The data and numerical values presented in this table correspond to the plotted values in Supplementary Fig. [5F-M](#MOESM1){ref-type="media"}. *L-Cys* [l]{.smallcaps}-cysteine, *ND* not detected, *PLP* pyridoxal phosphate

Non-enzymatic produced H~2~S in blood requires iron and VitB~6~ {#Sec8}
---------------------------------------------------------------

The majority of iron in the body is bound to heme, heme-like structures, and/or proteins^[@CR38]^. It is undetermined whether these biologically relevant forms of iron catalyze H~2~S production similar to free iron. Hemin (Supplementary Fig. [6A](#MOESM1){ref-type="media"}), a ferric protoporphyrin-IX group formed during RBC and heme turnover^[@CR39]^, and ferritin, the major iron-storage protein complex in tissues and circulation^[@CR40]^, dose dependently increased H~2~S production from L-Cys in the presence of PLP (Fig. [6a, b](#Fig6){ref-type="fig"}), which was dampened by EDTA (Fig. [6a](#Fig6){ref-type="fig"}). SIFT-MS headspace analysis confirmed hemin and ferritin catalyzed H~2~S production (Supplementary Fig. [6B](#MOESM1){ref-type="media"}). Similar to free Fe^3+^-driven H~2~S production (Fig. [2d](#Fig2){ref-type="fig"}), normoxic 20% O~2~ optimized hemin- and ferritin-catalyzed H~2~S production compared with hypoxic conditions (Supplementary Fig. [6C](#MOESM1){ref-type="media"}). H~2~S production in the circulation, specifically RBCs and plasma, was dependent on PLP (Supplementary Fig. [6D](#MOESM1){ref-type="media"}) and L-Cys, but not [l]{.smallcaps}-homocysteine (Supplementary Fig. [6E](#MOESM1){ref-type="media"}) and iron (Fig. [6c](#Fig6){ref-type="fig"}). Iron chelation via EDTA or diethylenetriaminepentaacetic acid (DTPA) inhibited H~2~S production in the RBCs and plasma (Fig. [6c, d, e, f](#Fig6){ref-type="fig"}), but not in the liver (Supplementary Fig. [6F](#MOESM1){ref-type="media"}). Iron is thus dispensable for enzymatic production in the liver, which is heavily CGL-driven (Fig. [1c](#Fig1){ref-type="fig"}), but not for non-enzymatic production in the circulation.Fig. 6Heme-bound iron catalyzes H~2~S production in vitro and in blood/plasma ex vivo. **a**, **b** Hemin (**a**; *n* = 6/group) and ferritin (**b**; *n* = 5/group) dose dependently catalyze H~2~S production from [l]{.smallcaps}-cysteine and PLP. Asterisk indicates the significance of the difference versus the [l]{.smallcaps}-cysteine and PLP control group; \**P* \< 0.05. **c** Iron-dependent H~2~S production from RBC lysate ± [l]{.smallcaps}-cysteine and PLP reaction mix, ±DTPA; *n* = 5/group. Asterisk indicates the significance of the difference between indicated groups; \**P* \< 0.05. **d**, **e** H~2~S production from RBC lysate (**d**; *n* = 4/group) or plasma (**e**; *n* = 3/group) ± theoretical inhibitors PAG and AOAA and ±iron chelator DTPA with the addition of [l]{.smallcaps}-cysteine and PLP. Asterisk indicates the significance of the difference versus the [l]{.smallcaps}-cysteine and PLP control group; \**P* *\<* 0.05. **f** H~2~S production from the reaction mixture of whole or lysed RBCs, [l]{.smallcaps}-cysteine, and PLP ± pretreatment of DTPA and ±Prot. K); *n* = 3/group. Asterisk indicates the significance of the difference versus non-lysed RBCs with no DTPA or Prot. K pretreatment; \**P* \< 0.05. All data were presented as mean ± SEM

To further confirm iron-catalyzed H~2~S production in the blood and plasma as non-enzymatic, we utilized several pharmacologic, biochemical, and genetic tools to rule out CBS, CGL, and/or 3-MST activity. Small-molecule inhibitors of CGL and CBS were first used to examine inhibition of potential enzymatic H~2~S production in RBCs (Fig. [6d](#Fig6){ref-type="fig"} and Supplementary Fig. [6G](#MOESM1){ref-type="media"}) and plasma (Fig. [6e](#Fig6){ref-type="fig"}). PAG, which inhibited enzymatic hepatic H~2~S production (Supplementary Fig. [5B](#MOESM1){ref-type="media"}) but not non-enzymatic H~2~S production in vitro (Fig. [5b](#Fig5){ref-type="fig"}), had no effect on RBC (Fig. [6d](#Fig6){ref-type="fig"}) or plasma (Fig. [6e](#Fig6){ref-type="fig"}) H~2~S production. Similarly, blood and plasma from *CGL* KO mice had no deficiencies in H~2~S production compared with WT mice (Fig. [1d](#Fig1){ref-type="fig"} and Supplementary Fig. [6E](#MOESM1){ref-type="media"}). These findings are consistent with the absence of CGL, and thus CGL-derived H~2~S, in RBCs^[@CR41]^. To rule out CBS, we first used AOAA, a purported general inhibitor of PLP-dependent enzymes, including CGL, CBS, and CAT^[@CR33]^. AOAA abolished H~2~S production in RBCs (Fig. [6d](#Fig6){ref-type="fig"} and Supplementary Fig. [6G](#MOESM1){ref-type="media"}) and plasma (Fig. [6e](#Fig6){ref-type="fig"}). However, as AOAA inhibits non-enzymatic H~2~S production in vitro (Fig. [5b](#Fig5){ref-type="fig"}), it cannot be used to accurately rule out CBS or enzymatic-mediated H~2~S production in the blood and serum. With this, we next utilized [d]{.smallcaps}-cysteine, which acts equally to L-Cys as a substrate for non-enzymatic H~2~S production (Fig. [4b](#Fig4){ref-type="fig"}) but cannot be used for enzymatic production (Supplementary Fig. [4A](#MOESM1){ref-type="media"}). [d]{.smallcaps}-Cysteine readily formed H~2~S in RBCs and this was abolished with the addition of AOAA and DPTA (Supplementary Fig. [6G](#MOESM1){ref-type="media"}). Thus, the iron dependence for H~2~S production in the blood is not related to the regulatory heme-containing prosthetic group on CBS^[@CR42]^ but via the non-enzymatic iron/PLP-catalyzed chemical reaction. To further rule out CAT/3-MST or other possible H~2~S-generating enzymes, proteinase K treatment of RBCs increased H~2~S production, which was abolished by DTPA (Fig. [6f](#Fig6){ref-type="fig"}). Taken together, H~2~S production in the blood and plasma is predominantly non-enzymatic and requires iron- and VitB~6~-coordinated catalysis of cysteine.

H~2~S exhibits toxic and beneficial characteristics, with the regulation and health-related impacts of its endogenous enzymatic production well understood^[@CR6],[@CR7],[@CR11]^. However, with non-enzymatic iron-catalyzed H~2~S production, questions remain regarding regulation and biological consequences. Iron-catalyzed production of reactive oxygen species (ROS) drives the pathophysiology of iron-overload disorders and hemolytic anemias, and is exacerbated when free iron is released^[@CR43]^. We hypothesized that under similar states of hemolytic anemia or dysregulated iron homeostasis, H~2~S production is altered and this contributes to the pathophysiology associated with these disorders. To begin testing this hypothesis, we examined the impact of whole vs. lysed RBCs on H~2~S production. Lysed RBCs increased iron-dependent H~2~S production capacity compared with non-lysed RBCs (Fig. [6f](#Fig6){ref-type="fig"}). Similarly, degradation of RBC proteins via Prot. K treatment increased iron-dependent H~2~S production in both whole and lysed RBCs (Fig. [6f](#Fig6){ref-type="fig"}). H~2~S production was greatest in lysed RBCs treated with Prot. K and this was dependent on iron (Fig. [6f](#Fig6){ref-type="fig"}). Catalytic activity of free Fe^3+^ was greater than the bound hemin form when compared in equimolar chemical reactions (Supplementary Fig. [6H](#MOESM1){ref-type="media"}). Thus, the integrity of RBCs and protein homeostasis regulate iron-catalyzed H~2~S, most likely through sequestration of iron into the bound vs. free faction, with the latter having increased catalytic potential. We additionally tested the effect of protein homeostasis on non-enzymatic H~2~S production in the brain (Supplementary Fig. [6I](#MOESM1){ref-type="media"}). H~2~S production was increased in whole brain extracts treated with Prot. K and was dependent on iron (Supplementary Fig. [6I](#MOESM1){ref-type="media"}). Thus, the regulation of protein homeostasis and cellular integrity on the iron-driven non-enzymatic H~2~S production is potentially not restricted to the circulation but common throughout tissues.

Discussion {#Sec9}
==========

In the current study, we examined enzymatic and non-enzymatic H~2~S production in organs and circulation. We determined enzymatic production is primarily driven by CGL and predominates in the liver and kidney, whereas non-enzymatic production prevails in the majority of other tissues. Non-enzymatic production of H~2~S was partial for cysteine as substrate and catalyzed by coordinated activities of VitB~6~ and iron at physiological temperatures, pH, and oxygen. Multiple biologically relevant forms of VitB~6~ and iron served as catalysts, whereas the state of RBCs and protein homeostasis impacted H~2~S production capacity. These results are summarized in Fig. [7](#Fig7){ref-type="fig"}.Fig. 7Experimental model of red blood cell state and tissue integrity impacting iron-catalyzed non-enzymatic H~2~S production. Iron in red blood cells and tissues catalyzes the production of H~2~S in coordination with VitB~6~ from the sulfur-containing amino acid cysteine at physiological temperatures, pH, and oxygen conditions. Multiple biologically relevant forms of VitB~6,~ PLP or pyridoxine, and iron, free or bound Fe^3+^/Fe^2+^, served as catalysts. Upon hemolysis, tissue damage, and/or degradation of iron- and heme-containing proteins, the catalytic potential of iron is increased and more H~2~S is produced. The biological significances of this increased H~2~S production, particularly in the context of hemolytic anemias and crises, are yet to be determined

Biological contexts and implications for the non-enzymatic production of H~2~S are not known, particularly if this reaction serves beneficial or detrimental roles. Nevertheless, the dietary, genetic, and hemolytic factors affecting VitB~6~ and iron bioavailability likely impact non-enzymatically produced H~2~S and this production may influence the physiological outcomes related to these factors. In the following discussion, we place our findings into biological contexts and established enzymatic and non-enzymatic sulfide-related fields.

Abnormal iron accumulation is associated with Alzheimer's^[@CR44]^, Parkinson's^[@CR45]^, hemolytic^[@CR46]^, and hemochromatosis diseases^[@CR47]^. Iron catalyzes the formation of ROS via the Fenton reaction^[@CR48]^. Although iron-catalyzed ROS serves beneficial functions such as signal transduction^[@CR49]^, it also damages macromolecules^[@CR50]^. Similar to ROS, H~2~S plays beneficial and detrimental roles dependent on dosage, tissue, and exposure route^[@CR51]^. Controlled enzymatic H~2~S production is generally beneficial^[@CR52]^. However, the consequences of non-enzymatic and theoretically less regulated H~2~S production are not known. Interestingly, H~2~S prevents the formation of ROS-induced protein aggregation found in neurodegenerative tissues^[@CR53]^ and prevents neurocognitive decline^[@CR54]^. In addition, deficient VitB~6~ status, of which we show suppresses iron-catalyzed H~2~S production, is a biomarker for neurocognitive decline in humans^[@CR55]^. Thus, iron may catalyze the production of harmful ROS concurrently with protective H~2~S and VitB~6~ status may shift the balance away from ROS to H~2~S. This may explain why chelation therapies targeting iron in neurodegenerative diseases have delivered mixed results^[@CR56]^. Future work entails examining downstream effects of this non-enzymatic production, such as posttranslational thiol-sulfhydration, tissue histology, and interventions to control the reaction under pathological settings of iron dysregulation.

Aerobic exercise provides metabolic and physiological benefits, but also induces RBC hemolysis^[@CR57]^. This is due to increased oxygen demands, osmotic perturbations, and compression of capillaries in muscles damaging RBCs^[@CR57]^. When comparing non-impact aerobic exercises vs. high-impact running, it was discovered that running produced more hemolysis and plasma-free hemoglobin due to foot strike and circulatory trauma^[@CR57]^. As H~2~S provides similar benefits to exercise, such as angiogenesis^[@CR16]^, one must ponder the extent non-enzymatic iron-catalyzed H~2~S provides in generating the benefits of exercise and running.

Enzymatic H~2~S production in solid tissues has been known for over 20 years^[@CR58]--[@CR60]^ and its VitB~6~-dependent mechanisms for over a decade^[@CR61],[@CR62]^. However, H~2~S levels and metabolism in blood and circulation are currently not well understood^[@CR41],[@CR63]^. Although circulating levels of free or bound H~2~S can be used as cardiovascular risk factors within individual trials^[@CR64]^, the source for this H~2~S is unclear. Previous studies suggest CBS and CGL are secreted into the bloodstream by the liver and vascular endothelial cells^[@CR65]^, whereas others propose production in the blood is derived via 3-MST^[@CR41]^. However, in our current study, we show H~2~S production derived from cysteine in the plasma/serum and RBCs is non-enzymatic and involves iron and VitB~6~. Although our study does not rule out the contributions of CBS, CGL, and 3-MST, it sets forth the theory that basal amounts of H~2~S in the bloodstream are of non-enzymatic origin. Interestingly, this is not the first study to establish iron's role in blood H~2~S metabolism. Although we report iron catalyzing the production of H~2~S, others show iron oxidizes and removes H~2~S from blood^[@CR41],[@CR66]^. Thus, iron has several roles in H~2~S biogenesis, metabolism, and detoxification.

We were initially puzzled that other SAAs, particularly homocysteine, did not serve as readily available H~2~S-producing substrates compared with cysteine for the chemical reaction. Homocysteine has only one extra carbon in the γ-position compared with cysteine and serves as substrate for enzymatic H~2~S production^[@CR6]^. With no stringent steric requirements in the chemical reaction compared with the enzymatic reaction, it is unclear why homocysteine did not produce H~2~S as rapidly as cysteine. An explanation is that PLP is expected to react with homocysteine and cysteine to form six-member tetrahydrothiazine and five-member thiazolidine rings^[@CR37]^, respectively. Consequently, the tetrahydrothiazine six-member ring is more thermodynamically stable compared with the five-member thiazolidine ring. Thus, it requires more time/energy for iron to break the six-member ring and/or access the exposed thiol from the broken bond between the sulfhydryl group and the imine carbon from homocysteine compared with cysteine.

There exists the possibility of outcompeting and side reactions resulting in additional products and impacting the H~2~S yield. Such products, although not detected in the methods utilized here, could be non-volatile sulfur-containing species that remain in solution, such as cysteine hydropersulfide and polysulfides. Due to the many oxidation states of sulfur^[@CR67]^, Fe^3+^-mediated oxidation could result in numerous additional sulfur species. Furthermore, H~2~S produced from the reaction may react with iron to form acid-labile iron-sulfide precipitates^[@CR68]^ and lower the detected H~2~S yield. Future studies are needed to capture all products pertaining to cysteine, VitB~6~, and iron, and how these impact basic biological process and pathophysiological outcomes.

Our results also provide insight regarding blood and tissue collection for downstream H~2~S production analysis. Blood collection tubes contain anti-coagulants, including EDTA. Our results indicate this metal chelator suppresses iron-catalyzed H~2~S production. Thus, EDTA use during sample collection can result in underestimating total H~2~S production capacity. Conversely, EDTA use would facilitate a focused analysis of enzymatic H~2~S production. In addition, we found the reductant DTT serves as substrate for H~2~S production via Fe^3+^ catalysis. This data could be used by investigators to avoid false positives when examining total sulfide pools in biological systems, particularly those that contain iron, when initial steps require the release of bound sulfane sulfur via the addition of a reductant^[@CR69]^. Thus, non-sulfur-containing reductants, such as tris(2-carboxyethyl)phosphine (TCEP), may lessen the occurrence of false-positive H~2~S detection.

In summary, we reveal a novel chemistry occurring under physiological conditions for iron and VitB~6~ coordinately and non-enzymatically catalyzing the production of H~2~S from cysteine. We show the importance of free vs. bound states of iron and the integrity of RBCs in controlling the robustness of this reaction. Ultimately, this study establishes a new area in hematological research with future directions to decipher downstream effects of altered iron-catalyzed H~2~S in tissues most affected by hemolytic crisis, hemorrhage, and iron overload, and to develop cysteine- and VitB~6~-based interventions for the treatment of these disorders.

Methods {#Sec10}
=======

Animal studies {#Sec11}
--------------

All experiments were performed with the approval of the Institutional Animal Care and Use Committee from the Cleveland Clinic Lerner Research Institute, protocol number 2016--1778. Animals were bred and maintained under standard housing conditions in the Cleveland Clinic Biological Resource Unit with ad libitum access to food (Envigo \#2918) and water, 12 h light/12 h dark cycles, temperature between 20 and 23 °C with 30--70% relative humidity, and weaned between 3 and 4 weeks of age. Tissues from mice used in Fig. [1c, d](#Fig1){ref-type="fig"} and Supplementary Fig. [1A-C](#MOESM1){ref-type="media"} were 6-week-old and that used in Fig. [6f](#Fig6){ref-type="fig"} and Supplementary Fig. [6D](#MOESM1){ref-type="media"} were 1-year-old *CGL* WT and KO mice on a mixed 129/C57BL/6 background as previously described^[@CR15],[@CR70]^, and those in Fig. [6c](#Fig6){ref-type="fig"} were 6-month-old C57BL/6 male mice. Tissues used in the remaining figures are adult 6--8-month-old C57BL/6J male mice (Jackson Laboratory).

RBC hemolysis {#Sec12}
-------------

Mice were anesthetized with isoflurane and blood collected via retro-orbital bleed and immediately placed into lithium-heparin-coated capillary tubes (Terumo \#T-MLH). Tubes were centrifuged to separate RBCs from the plasma. After removing the plasma supernatant, equal volume of PBS was added to the packed RBC pellet and mixed gently to resuspend the RBCs. The RBC suspension was then split in half, with one half flash frozen in liquid nitrogen and then thawed at room temperature for a total of three rounds to facilitate hemolysis. The samples were then spun down and the RBC lysates (supernatant) were ready for further determination of H~2~S production.

Lead acetate/lead sulfide method for H~2~S determination {#Sec13}
--------------------------------------------------------

H~2~S production was measured using the lead acetate/lead sulfide method^[@CR21]^. Briefly, 150 µL of reaction mixture was performed in either PBS or cell culture media DMEM or DMEM/F12. The reaction mixture contained 10 mM L-Cys (Sigma \#168149) or other SAAs [d]{.smallcaps}-cysteine (Sigma \#30095), [l]{.smallcaps}-homocysteine (Sigma \#69453), [dl]{.smallcaps}-homocysteine (Sigma \#H4628), [l]{.smallcaps}-methionine (Sigma \#64319), glutathione (Sigma \#G6013), and NAC (Sigma \#A7250) as substrate, and 1 mM PLP (Sigma \#9255) or pyridoxal (Sigma \#271748) as cofactor, and placed in 96-well assay plates and incubated with the addition of FeCl~3~ (Alfa Aesar \#12357), FeCl~2~ (Alfa Aesar \#31141), hemin (Sigma \#51290), ferritin (Sigma \#F4503), or other metal irons Mn^2+^ (Sigma \#203724), Zn^2+^ (LabChem \#LC270701), Cu^2+^ (Sigma \#209198), Pb^2+^ (Sigma \#316512), Al^3+^ (Sigma \#294713), Ca^2+^ (Sigma \#223506), and Mg^2+^ (Sigma \#M-9397) as non-tissue-derived catalysts. The concentration of the catalysts used was 50 µM or as indicated in the figures. Other organic sulfur compounds, including artificial garlic oil blend (Sigma W530316) and two major garlic components, DATS (Sigma SMB00289) and DADS (Sigma SMB00378), DTT (Sigma 43815) and 2ME (Fisher Scientific C3446I), were also tested as substrates. The garlic oil blend was added into the chemical reaction at 1000-fold dilution and votexed before the incubation, and others were used at 10 mM working concentrations. Filter paper, embedded with lead acetate (Sigma \#316512), was placed above the assay plate and incubated at 37 °C air chamber between 1 and 24 h until a desirable amount of lead sulfide was detected for proper quantification. To determine the H~2~S production under anaerobic condition, the chemical mixture of L-cys/PLP/Fe^3+^ in PBS was run in 96-well format in a hypoxia/anoxia chamber (COY Laboratory Products, Inc.) with the oxygen (O~2~) level set to 0% with nitrogen (N~2~) resulting in an actual hypoxic environment of 0.1--0.2% O~2~. Similar procedures were used when measuring the H~2~S production capacity of tissues, blood, and plasma. In these cases, 100 µg tissue homogenate in passive lysis buffer (Promega \#1941) or 10--20 µL of whole RBCs or RBC lysate, or plasma/serum was added to the 150 µL reaction mixture containing 10 mM L-Cys and 1 mM PLP, followed by the same protocol as described above for determination of H~2~S production. Tissue extracts used in Fig. [1e](#Fig1){ref-type="fig"} were pretreated ex vivo with Proteinase K (Prot. K) (Sigma \# 3115879001) in 37 °C water bath for 1 h, to remove all potential enzymatic activity prior to performing H~2~S production. In reactions pretreated with the inhibitors, 10 mM EDTA (Sigma \#5134), 100 µM DTPA (Sigma \#D6518), 2 mM PAG (Sigma \#P7888), or 2 mM AOAA (Sigma \#C13408) were added to the reaction mixture prior to the addition of the chemical or tissue catalyst.

Head space measurement of H~2~S production {#Sec14}
------------------------------------------

H~2~S production from reaction mixture of L-Cys, PLP, and iron was quantified using two instruments: (1) the Jerome J605 as shown in Supplementary Fig. [3B](#MOESM1){ref-type="media"}, a gold film H~2~S analyzer^[@CR44]^, and (2) the SIFT-MS (VOICE200R SIFT-MS instrument, Syft Technologies, Ltd, Christchurch, New Zealand), measuring the product ions generated in the reaction of H~3~O^+^ in H~3~O^+^ + H~2~S ↔ H~3~S^+^ + H~2~O, being the mass-to-charge (*m*/*z*) 35 product ion^[@CR26],[@CR27]^. Briefly, 1 mL of reaction mixture containing supraphysiological concentrations of L-Cys (10 mM), PLP (1 mM), and Fe^3+^ (50 µM), or physiological concentrations of L-Cys (500 µM), PLP (500 nM), and Fe^3+^ (50 µM) were placed in headspace vials (for H~2~S detection in the Jerome J605, Wheaton \#225277 6 mL headspace vials; for H~2~S detection in the SYFT-MS, Agilent 20 mL headspace vials) and sealed with aluminum seal caps containing a polytetrafluoroethylene (PTFE)/silicone septa (Restek \#21763). Reaction mixtures were incubated at 37 °C for a desired amount of time (for H~2~S detection in the Jerome J605, 1 h with supraphysiological reaction mixture and 6 h with physiological reaction mixture; for H~2~S detection in the SIFT-MS, 30 min at 37 °C). Afterwards, headspace air was sampled via needle and syringe, 1 mL for Jermone J605 analysis and 15 mL for SIFT-MS, and injected directly into the instrument for detection. The concentration of H~2~S with displayed at p.p.b. for the Jerome J605 and at p.p.m. for SIFT-MS. Headspace air was also sampled and injected to SIFT-MS, measuring the full mass spectrum over the range of *m*/*z* shown in H~3~O^+^ reagent ion.

H~2~S and pyruvate production with fluorescent probe detection {#Sec15}
--------------------------------------------------------------

Kinetic H~2~S production was measured using AzMC (Sigma \#802409), which is a fluorogenic probe selectively reduced in the presence of H~2~S producing 7-amino-4-methylcoumarin^[@CR29]^ and detectable with excitation wavelength Exc 350 nm and emission wavelength Emi 445 nm. Briefly, 150 µL of reaction mixtures containing combinations of 10 mM L-Cys, 1 mM PLP, and 50 µM Fe^3+^ in the presence of 100 μM AzMC probe were placed in 96-well plates and analyzed at various timepoints on SpectraMax i3 multimode plate reader through bottom reading (37 °C, *λ*~Exc/Emi~ = 350/445 nm, photomultiplier tube (PMT): medium) with 10 min interval. Similarly, kinetic pyruvate production was measured using a plate-based pyruvate assay kit (Abcam \#ab65342). Briefly, in a clear-bottom 96-well plate, 50 µL of H~2~S reaction mixture (10 mM L-cys, 1 mM PLP ± 50 µM FeCl~3~ in PBS) was mixed with 50 µL of pyruvate colorimetric reaction mixture. The pyruvate product was analyzed on SpectraMax i3 multimode plate reader through bottom reading (37 °C, *λ* = 570 nm) with 30 min time interval.

LC-MS/MS analysis of standards, intermediates, and products {#Sec16}
-----------------------------------------------------------

Chemical reactions containing individual L-Cys (10 mM), PLP (1 mM), or FeCl~3~ (50 µM), or a mixture of the above compounds were incubated at 37 °C for 3 h prior to freezing at −20 °C overnight. A full reaction mixture without 37 °C incubation was put in freezer at −20 °C immediately, serving as a negative control to the full reaction mixture with 37 °C incubation. All samples were submitted for untargeted LC-MS/MS analysis. The samples were thawed, placed in high-performance LC (HPLC) vials, and the vials were place in the chilled autosampler (4 °C). The LC-MS instrument was configured with an HPLC containing two Shimadzu LC-20AD Pumps, DGU-203R Autosampler, and CBM-20A Communications Module, and a time-of-flight (TOF) high-resolution accurate-mass spectrometer (SCIEX TripleTOF 5600). The HPLC column was a Phenomenex Prodigy 5μ ODS, 2.0 × 150 mm reversed-phase column. Sample injection volume was 5 μL and the eluent flow rate was 0.2 mL/min. The HPLC used a gradient formulated from different proportions of Eluent A (water + 0.2% formic acid) and Eluent B (methanol + 0.2% formic acid). The gradient began at 100% Eluent A and remained there for 3 min. Next, a linear gradient from 100% Eluent A to 100% Eluent B over 6 min was formulated and the system then remained at 100% Eluent B for 6 min. The system was then returned to 100% Eluent A for 10 min, re-equilibrating the chromatographic column in preparation for the next injection. Each sample was injected four times to undergo four different MS analyses as follows: (1) a full-scan positive ion MS TOF (20--750 *m*/*z*) survey scan was collected and used to trigger data-dependent MS/MS analysis of the most intense ion from the survey scan. (2) This TOF-IDA (Information-Dependent Acquisition) analysis was repeated in the negative ion mode. (3) Full-scan positive ion MS TOF (40--750 *m*/*z*) survey scans were followed by MS/MSall (SWATH) data collection, using 18 product ion scans with 40 *m*/*z* widths to cover the entire survey scan mass range. (4) This TOF-SWATH (Sequential Window Acquisition of all Theoretical fragment ion spectra) analysis was repeated in the negative ion mode. Data were analyzed by generating full scan extracted ion chromatograms (XICs) generated from the formula weights of the compounds expected to be present using positive/negative ion TOF analysis. The XICs for L-Cys and cysteine-aldimine/quinonoid/thiazolidine were analyzed at positive ion TOF with mass of 122.0166 ± 0.0029 Da and 351.010 ± 0.006 Da, respectively. The XICs for aldimine and pyruvate were analyzed at negative ion TOF with mass from 314.75 to 315.25 Da and from 86.75 to 87.25 Da, respectively.

UV/Vis measurement of PLP absorbance {#Sec17}
------------------------------------

One hundred and fifty microliters of PBS containing 1 mM PLP in the absence or presence of the SAAs previously listed was placed in 96-well assay plates and analyzed on a SpectraMax i3 multimode plate reader at an absorbance spectrum between 280 and 460 nm at room temperature.

Immunoblot and Coomassie staining for protein expression {#Sec18}
--------------------------------------------------------

Protein analysis was performed via western blotting on tissue homogenates in passive lysis buffer (Promega), separated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane (Whatman) and blotted for CGL (ab151769 Abcam), CBS (ab135626 Abcam), MST (\#85211 Abcam), or α-Tubulin (\#4074 Abcam), followed by horseradish peroxidase-conjugated secondary anti-rabbit antibody (\#97051 Abcam). Proteins were visualized using SuperSignal West Femto Maximum Sensitivty Substrate (Thermo Scientific \#34096) on an Amersham Imager 600 (General Electric) and sizes determined using the PageRuler Plus Prestained (26619 Thermo Fisher). After blotting and washing, the membranes were stained using Coomassie blue, to determine the relatively equal amount of tissue proteins loaded.

Statistics and reproducibility {#Sec19}
------------------------------

Data are displayed as means ± SD or means ± SEM with *n*-values between 3 and 6 as indicated in the figure legends. The majority of the experiments were performed at least twice independently with multiple technical replicates performed for each independent experiment. Statistical significance was assessed in GraphPad Prism and/or Microsoft Excel using Student's *t*-tests to compare values between two specific groups and one-way analysis of variance with a Tukey's multiple comparison test for comparing more than two groups in a single data set. A *P*-value of 0.05 or less was deemed statistically significant and statistical details are found in the figures and figure legends. Quantifications of lead acetate/lead sulfide H~2~S production capacity images were performed using the IntDen measurement function in ImageJ software and normalized to the respective control group after subtracting the background.

Reporting summary {#Sec20}
-----------------

Further information on research design is available in the [Nature Research Reporting Summary](#MOESM2){ref-type="media"} linked to this article.

Supplementary information
=========================

 {#Sec21}

Supplemental Figures and Table Reporting Summary

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1038/s42003-019-0431-5.

We thank Kai Chen at the California Institute of Technology and Dr Vijay Krishna at the Cleveland Clinic Lerner Research Institute for valuable technical suggestions and chemistry related insights. This work was funded by NIH/NIA grant R00 AG050777 and Seed Funds from the Cleveland Clinic Lerner Research Institute to C.H. and a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada to R.W.

J.Y. and C.H. conceptualized the project. R.W. contributed valuable *CGL* KO mouse models. R.D. contributed access and insight into the SIFT-MS (SYFT-MS). J.Y., P.M., D.G., B.W., and C.H. performed experiments and analyzed data. J.Y. and C.H. wrote the paper.

The authors declare that the majority of the data supporting the findings of this study are available within the paper and its [supplementary information files](#MOESM1){ref-type="media"}. Additionally, raw data are available from the corresponding author upon reasonable request.

The authors declare no competing interests.
